NGM Biopharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Allurion Technologies merger with Compute Health Acquisition
We advised the capital markets adviser on the de-SPAC transaction
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Korro Bio $117 million private placement
The financing is expected to close immediately prior to the completion of Korro Bio’s merger with Frequency Therapeutics
Bausch + Lomb $1.75 billion financing for acquisition of certain Novartis assets
We are advising Bausch + Lomb on the financing
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Noile-Immune Biotech ¥3.1 billion global IPO
The shares are listed on the Tokyo Stock Exchange
IDEAYA Biosciences $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
ATI Physical Therapy $100 million convertibles offering and recapitalization
We advised an ad hoc group of term lenders in connection with the transaction
Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market